Cargando…

Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933

PURPOSE: NRG Oncology's RTOG 0933 demonstrated benefits to memory preservation after hippocampal avoidant whole-brain radiation therapy (HA-WBRT), the avoidance of radiation dose to the hippocampus (using intensity modulated radiation planning and delivery techniques) during WBRT, supporting th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bovi, Joseph A., Pugh, Stephanie L., Sabsevitz, David, Robinson, Clifford G., Paulson, Eric, Mehta, Minesh P., Gondi, Vinai, Kundapur, Vijayananda, Shahin, Mark S., Chao, Samuel T., Machtay, Mitch, DeNittis, Albert S., Laack, Nadia N., Greenspoon, Jeffrey N., Moore, Kathleen N., Huang, Jiayi, Dominello, Michael M., Kachnic, Lisa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817553/
https://www.ncbi.nlm.nih.gov/pubmed/31673651
http://dx.doi.org/10.1016/j.adro.2019.07.006
_version_ 1783463445119631360
author Bovi, Joseph A.
Pugh, Stephanie L.
Sabsevitz, David
Robinson, Clifford G.
Paulson, Eric
Mehta, Minesh P.
Gondi, Vinai
Kundapur, Vijayananda
Shahin, Mark S.
Chao, Samuel T.
Machtay, Mitch
DeNittis, Albert S.
Laack, Nadia N.
Greenspoon, Jeffrey N.
Moore, Kathleen N.
Huang, Jiayi
Dominello, Michael M.
Kachnic, Lisa A.
author_facet Bovi, Joseph A.
Pugh, Stephanie L.
Sabsevitz, David
Robinson, Clifford G.
Paulson, Eric
Mehta, Minesh P.
Gondi, Vinai
Kundapur, Vijayananda
Shahin, Mark S.
Chao, Samuel T.
Machtay, Mitch
DeNittis, Albert S.
Laack, Nadia N.
Greenspoon, Jeffrey N.
Moore, Kathleen N.
Huang, Jiayi
Dominello, Michael M.
Kachnic, Lisa A.
author_sort Bovi, Joseph A.
collection PubMed
description PURPOSE: NRG Oncology's RTOG 0933 demonstrated benefits to memory preservation after hippocampal avoidant whole-brain radiation therapy (HA-WBRT), the avoidance of radiation dose to the hippocampus (using intensity modulated radiation planning and delivery techniques) during WBRT, supporting the hypothesis of hippocampal radiosensitivity and associated memory specificity. However, some patients demonstrated cognitive decline, suggesting mechanisms outside hippocampal radiosensitivity play a role. White matter injury (WMI) has been implicated in radiation therapy–induced neurocognitive decline. This secondary analysis explored the relationship between pretreatment WMI and memory after HA-WBRT. METHODS AND MATERIALS: Volumetric analysis of metastatic disease burden and disease-unrelated WMI was conducted on the pretreatment magnetic resonance image. Correlational analyses were performed examining the relationship between pretreatment WMI and Hopkins Verbal Learning Test-Revised (HVLT-R) outcomes at baseline and 4 months after HA-WBRT. RESULTS: In the study, 113 patients received HA-WBRT. Of 113 patients, 33 underwent pretreatment and 4-month posttreatment HVLT testing and pretreatment postcontrast volumetric T1 and axial T2/fluid-attenuated inversion recovery magnetic resonance imaging. Correlation was found between larger volumes of pretreatment WMI and decline in HVLT-R recognition (r = 0.54, P < .05), and a correlational trend was observed between larger volume of pretreatment WMI and decline in HVLT-R delayed recall (r = 0.31, P = .08). Patients with higher pretreatment disease burden experienced a greater magnitude of stability or positive shift in HVLT-R recall and delayed recall after HA-WBRT (r = –0.36 and r = –0.36, P < .05), compared to the magnitude of stability or positive shift in those with lesser disease burden. CONCLUSIONS: In patients receiving HA-WBRT for brain metastases, extent of pretreatment WMI predicts posttreatment memory decline, suggesting a mechanism for radiation therapy–induced neurocognitive toxicity independent of hippocampal stem cell radiosensitivity. Stability or improvement in HVLT after HA-WBRT for patients with higher pretreatment intracranial metastatic burden supports the importance of WBRT-induced intracranial control on neurocognition.
format Online
Article
Text
id pubmed-6817553
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68175532019-10-31 Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933 Bovi, Joseph A. Pugh, Stephanie L. Sabsevitz, David Robinson, Clifford G. Paulson, Eric Mehta, Minesh P. Gondi, Vinai Kundapur, Vijayananda Shahin, Mark S. Chao, Samuel T. Machtay, Mitch DeNittis, Albert S. Laack, Nadia N. Greenspoon, Jeffrey N. Moore, Kathleen N. Huang, Jiayi Dominello, Michael M. Kachnic, Lisa A. Adv Radiat Oncol Central Nervous System PURPOSE: NRG Oncology's RTOG 0933 demonstrated benefits to memory preservation after hippocampal avoidant whole-brain radiation therapy (HA-WBRT), the avoidance of radiation dose to the hippocampus (using intensity modulated radiation planning and delivery techniques) during WBRT, supporting the hypothesis of hippocampal radiosensitivity and associated memory specificity. However, some patients demonstrated cognitive decline, suggesting mechanisms outside hippocampal radiosensitivity play a role. White matter injury (WMI) has been implicated in radiation therapy–induced neurocognitive decline. This secondary analysis explored the relationship between pretreatment WMI and memory after HA-WBRT. METHODS AND MATERIALS: Volumetric analysis of metastatic disease burden and disease-unrelated WMI was conducted on the pretreatment magnetic resonance image. Correlational analyses were performed examining the relationship between pretreatment WMI and Hopkins Verbal Learning Test-Revised (HVLT-R) outcomes at baseline and 4 months after HA-WBRT. RESULTS: In the study, 113 patients received HA-WBRT. Of 113 patients, 33 underwent pretreatment and 4-month posttreatment HVLT testing and pretreatment postcontrast volumetric T1 and axial T2/fluid-attenuated inversion recovery magnetic resonance imaging. Correlation was found between larger volumes of pretreatment WMI and decline in HVLT-R recognition (r = 0.54, P < .05), and a correlational trend was observed between larger volume of pretreatment WMI and decline in HVLT-R delayed recall (r = 0.31, P = .08). Patients with higher pretreatment disease burden experienced a greater magnitude of stability or positive shift in HVLT-R recall and delayed recall after HA-WBRT (r = –0.36 and r = –0.36, P < .05), compared to the magnitude of stability or positive shift in those with lesser disease burden. CONCLUSIONS: In patients receiving HA-WBRT for brain metastases, extent of pretreatment WMI predicts posttreatment memory decline, suggesting a mechanism for radiation therapy–induced neurocognitive toxicity independent of hippocampal stem cell radiosensitivity. Stability or improvement in HVLT after HA-WBRT for patients with higher pretreatment intracranial metastatic burden supports the importance of WBRT-induced intracranial control on neurocognition. Elsevier 2019-07-16 /pmc/articles/PMC6817553/ /pubmed/31673651 http://dx.doi.org/10.1016/j.adro.2019.07.006 Text en Crown Copyright © 2019 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Central Nervous System
Bovi, Joseph A.
Pugh, Stephanie L.
Sabsevitz, David
Robinson, Clifford G.
Paulson, Eric
Mehta, Minesh P.
Gondi, Vinai
Kundapur, Vijayananda
Shahin, Mark S.
Chao, Samuel T.
Machtay, Mitch
DeNittis, Albert S.
Laack, Nadia N.
Greenspoon, Jeffrey N.
Moore, Kathleen N.
Huang, Jiayi
Dominello, Michael M.
Kachnic, Lisa A.
Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933
title Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933
title_full Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933
title_fullStr Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933
title_full_unstemmed Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933
title_short Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933
title_sort pretreatment volume of mri-determined white matter injury predicts neurocognitive decline after hippocampal avoidant whole-brain radiation therapy for brain metastases: secondary analysis of nrg oncology radiation therapy oncology group 0933
topic Central Nervous System
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817553/
https://www.ncbi.nlm.nih.gov/pubmed/31673651
http://dx.doi.org/10.1016/j.adro.2019.07.006
work_keys_str_mv AT bovijosepha pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT pughstephaniel pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT sabsevitzdavid pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT robinsoncliffordg pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT paulsoneric pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT mehtamineshp pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT gondivinai pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT kundapurvijayananda pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT shahinmarks pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT chaosamuelt pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT machtaymitch pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT denittisalberts pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT laacknadian pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT greenspoonjeffreyn pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT moorekathleenn pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT huangjiayi pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT dominellomichaelm pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933
AT kachniclisaa pretreatmentvolumeofmrideterminedwhitematterinjurypredictsneurocognitivedeclineafterhippocampalavoidantwholebrainradiationtherapyforbrainmetastasessecondaryanalysisofnrgoncologyradiationtherapyoncologygroup0933